New aspects of sepsis pathophysiology in critically ill;Novi aspekti patofiziologije sepse kod kritično obolelih

Vojnosanitetski Pregled

Volumn 69, Issue 1, 2012, Pages 58-68

  Djordjević, Dragan ^a   Šurbatović, Maja ^a   Ugrinović, Djordje ^b   Radaković, Sonja ^a   Jevdjić, Jasna ^b   Filipović, Nikola ^a   Romić, Predrag ^a   Jovanović, Duško ^a  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b Univerzitet u Kragujevcu   (Serbia)

Author keywords

Critical illnes; Immunologic factors; Pathology; Physiology; Prognosis; Sepsis; Shock

Indexed keywords

IMMUNOLOGIC FACTOR;

ARTICLE; CRITICALLY ILL PATIENT; HUMAN; PATHOPHYSIOLOGY; SEPSIS;

CRITICAL ILLNESS; HUMANS; MULTIPLE ORGAN FAILURE; SEPSIS; SHOCK, SEPTIC;

EID: 84855709429     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP1201058D     Document Type: Article

References (74)

1. Šurbatović M, Filipović N, Jevd{stroke}ić J. Infection, the syndrome of systemic inflammatory response, sepsis, septic shock, the syndrome of multiple organic disfunction. Anestezija, reanimacija, transfuzija 2000; 28(1-2): 111-2. (Serbian)
2. Šurbatović M, Jevd{stroke}ić J, Filipović N. Application of the score of sepsis in 30 patients with sepsis of various severity. Anestezija, reanimacija, transfuzija 2000; 28(1-2): 113-7. (Serbian)
3. Šurbatović M., Krgović M. Myocard disfunction in sepsis. Anestezija, reanimacija, transfuzija 2001; 29(1-2): 19-23.
4. Šurbatović M, Filipović N, Protić S, Jovanović K. Is the concentration of tumor necrosis factor-alpha (TNF alpha) more reliable than SAPS II score for the prediction of mortality risk in severe sepsis. Anestezija, reanimacija, transfuzija 2001; 29(1-2): 25-8. (Serbian)
5. Šurbatović M, Jovanović K, Kataranovski M, Vojvodić D, Filipović N. Significance of pro-and anti-inflammatory cytokine for the development of the syndrome of multiple organic disfunction in trauma and sepsis. Anaesth Iug 2002; 18(3-4): 92-103. (Serbian)
6. Šurbatović M, Jovanović K, Vojvodić D, Filipović N, Babić D. Proinflammatory cytokine in polytraumatized patients with sepsis caused by various bacteria and the correlation between clinical image severity and outcome and the type of bacterial cause. Anestezija i intenzivna terapija 2003; 26: 109-20. (Serbian)
7. Šurbatović M, Jovanović K, Vojvodić D. Correlation between tumor necrosis factor-alpha and the severity and outcome of sepsis. Anestezija i intenzivna terapija 2003; 26: 31-49. (Serbian)
8. Šurbatović M, Jovanović K, Vojvodić D, Filipović N, Babić D. Importance of determination of proinflammatory cytokines in the blood of polytraumatized patients with sepsis. Vojnosanit Pregl 2004; 61(2): 137-43. (Serbian)
9. Šurbatović M, Jovanović K, Filipović N, Radaković S. Significance of interleukin 8 (IL)-8 as a predictor of clinical image severity and the outcome of multiple organ dysfunction syndrome in sepsis and/or asepsis. Anestezija i intenzivna terapija 2005; 28(1): 7-17. (Serbian)
10. Šurbatović M, Jovanović K, Radaković S, Filipović N. Pathophysiological aspects of severe acute pancreatitis-associated lung injury. Srp Arh Celok Lek 2005; 133(1-2):76-81. (Serbian)
11. Šurbatović M, Radaković S, Jovanović K, Romić P. New strategies in multiple organ dysfunction syndrome therapy for sepsis. Srp Arh Celok Lek 2005; 133(7-8):379-83. (Serbian)
12. Jevd{stroke}ić J, Šurbatović M, Filipović N, Radaković S. Characteristics of immune response in urosepsis. Vojnosanit Pregl 2006; 63(6): 601-3 (Serbian)
13. Šurbatovic M, Filipovic N, Radakovic S. Sepsis, is there anything new? Anestezija i intenzivna terapija 2006; 56(Suppl. 2): 35-7.
14. Šurbatović M, Filipović N, Slavković Z. Radaković S. Infection and inflammation in sepsis. Vojnosanit Pregl 2006; 63(2):163-8
15. Surbatovic M, Filipovic N, Radakovic S, Stankovic N, Slavkovic Z. Immune cytokine response in combat casualties: blast or explosive trauma with or without secondary sepsis. Mil Med 2007; 172(2): 190-5.
16. Šurbatović M, Jevtić M, Filipović N, Radaković S. Imunoinflamatorna kaskada sepse. Anestezija reanimacija transfuzija 2007; 35(1-2): 114-7. (Serbian)
17. Šurbatović M, Jevtić M, Filipović N, Radaković S. Could sepsis mediatos be a therapeutic target? Anestezija reanimacija transfuzija 2007; 35(1-2):107-10. (Serbian)
18. Šurbatović M, D{stroke}ord{stroke}ević D. Pathophysiology of severe acute pancreatitis as a systemic disease. Anestezija i intenzivna terapija 2008; (Suppl):113-7
19. Jevd{stroke}ić J, Šurbatović M, Drakulić-Miletić S, Vukićević V. Application of new therapy strategies in treating sepsis and septic shock in the Intensive treamtnet unit, Clinical center Kragujevac. Srp Arh Celok Lek 2008; 136(5-6): 248-52. (Serbian)
20. Surbatovic M, Radakovic S, Jevtic M, Filipovic N, Romic P, Popovic N, et al. Predictive value of serum bicarbonate, arterial base deficit/excess and SAPS III score in critically ill patients. Gen Physiol Biophys 2009; 28 Spec No: 271-6.
21. Vučeljić M, Šurbatović M, Vujanić S. S-100-protein in patients with severe sepsis. J Med Biochem 2009; 28(1): 46-9. (Serbian)
22. Šurbatović M, Jevtić M, Filipović N, Radaković S, Marković M. Sepsis mediator interactions. Anestezija reanimacija transfuzija 2009; 37(1-2):74-7. (Serbian)
23. Surbatovic M, Grujic K, Cikota B, Jevtic M, Filipovic N, Romic P, et al. Polymorphisms of genes encoding tumor necrosis factoralpha, interleukin-10, cluster of differentiation-14 and interleukin-1ra in critically ill patients. J Crit Care 2010; 25(3): 542. e1-8.
24. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348(2): 138-50.
25. Hotchkiss RS, Chang KC, Grayson MH, Tinsley KW, Dunne BS, Davis CG, et al. Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci U S A 2003; 100(11): 6724-9.
26. Brunn GJ, Platt JL. The etiology of sepsis: turned inside out. Trends Mol Med 2006; 12(1): 10-6.
27. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007; 81(1): 1-5.
28. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301(23): 2445-52.
29. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 2007; 11(2): R47.
30. Kawamoto T, Ii M, Kitazaki T, Iizawa Y, Kimura H. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain. Eur J Pharmacol 2008; 584(1): 40-8
31. Rice TW, Wheeler AP, Bernard GR, Vincent JL, Angus DC, Aikawa N, et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med 2010; 38(8):1685-94.
32. Tidswell M, Tillis W, Larosa SP, Lynn M, Wittek AE, Kao R, et al. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med 2010; 38(1): 72-83.
33. Bianchi ME. HMGB1 loves company. J Leukoc Biol 2009; 86(3): 573-6.
34. Hreggvidsdottir HS, Ostberg T, Wahamaa H, Schierbeck H, Aveberger AC, Klevenvall L. et al.: The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol 2009; 86(3):655-62.
35. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA 2010; 107(26): 11942-7.
36. Robert SM, Sjodin H, Fink MP, Aneja RK. Preconditioning with High Mobility Group Box 1 (HMGB1) induces lipoteichoic acid (LTA) tolerance. J Immunother 2010; 33(7): 663-71.
37. Levy RM, Mollen KP, Prince JM, Kaczorowski DJ, Vallabhaneni R, Liu S, et al. Systemic inflammation and remote organ injury following trauma require HMGB1. Am J Physiol Regul Integr Comp Physiol 2007; 293(4): R1538-44.
38. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 2006; 26(2): 174-9.
39. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002; 99(19): 12351-6.
40. Yang R, Uchiyama T, Alber SM, Han X, Watkins SK, Delude RL, et al. Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit Care Med 2004; 32(7): 1453-9.
41. Yang H, Tracey KJ. High mobility group box 1 (HMGB1). Crit Care Med 2005; 33(12 Suppl): S472-4.
42. Fink MP. Ethyl pyruvate: a novel anti-inflammatory agent. J Intern Med 2007; 61(4): 349-62.
43. Fink MP. Ethyl pyruvate. Curr Opin Anaesthsiol 2008: 21(2): 160-7.
44. Yang R, Shaufl AL, Killeen ME, Fink MP. Ethyl pyruvate ameliorates liver injury secondary to severe acute pancreatitis. J Surg Res 2009; 153(2): 302-9.
45. Cruz RJ Jr, Harada T, Sasatomi E, Fink MP. Effects of ethyl pyruvate and other α-keto carboxylic acid derivatives in a rat model of multivisceral ischemia and reperfusion. J Surg Res 2011; 165(1): 151-7.
46. Kao KK, Fink MP. The biochemical basis for the antiinflammatory and cytoprotective actions of ethyl pyruvate and related compounds. Biochem Pharmacol 2010; 80(2): 151-9.
47. Fink MP. The therapeutic potential of pyruvate. J Surg Res 2010; 164(2): 218-20.
48. Cai B, Deitch EA, Ulloa L. Novel insights for systemic inflammation in sepsis and hemorrhage. Mediators Inflamm 2010; 2010: 642462.
49. Mann H. The pharmacologic horizon of sepsis therapy. Critical Connections 2006; 5(4): 17
50. Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009; 37(1 Suppl): S30-7.
51. Singer M, De Santis V, Vitale D, Jeffcoate W. Multiorgan failure is an adaptive, endocrine-mediated, metabolic response to overwhelming systemic inflammation. Lancet 2004; 364(9433): 545-8.
52. Singer M. Cellular dysfunction in sepsis. Clin Chest Med 2008; 29(4): 655-60, viii-ix.
53. Huang YCT. Monitoring Oxygen Delivery in the Critically ill. Chest 2005; 128(5 Suppl 2): 554S-60S.
54. Singer M. Metabolic failure. Crit Care Med 2005; 33(12 Suppl): 539-42.
55. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360(9328): 219-23.
56. Svistunenko DA, Davies N, Brealey D, Singer M, Cooper CE. Mitochondrial dysfunction in patients with severe sepsis: an EPR interrogation of individual respiratory chain components. Biochim Biophys Acta 2006; 1757(4): 262-72.
57. Carré JE, Orban JC, Re L, Felsmann K, Iffert W, Bauer M, et al. Survival in critical illness is associated with early activation of mitochondrial biogenesis. Am J Respir Crit Care Med 2010; 182(6): 745-51.
58. Szabo C. Cytopathic Hypoxia in Circulatory Shock: The Role of Poly (ADP-Ribose) Synthetase Activation. In: Evans T, Fink M, editors. Mechanisms of organ diysfunction in critical illness. Berlin: Springer-Verlag; 2002. p. 40-51.
59. Fink MP. Bench-to-bedside review: Cytopathic hypoxia. Crit Care 2002; 6(6): 491-9.
60. Leverve XM. Derangements in Cellular Oxygen Metabolism. In: Evans T, Fink M, editors. Mechanisms of organ diysfunction in critical illness. Berlin: Springer-Verlag; 2002. p. 52-68.
61. Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Crit Care Med 2007; 35(9 Suppl): S441-8.
62. Fink MP. Administration of exogenous cytochrome c as a novel approach for the treatment of cytopathic hypoxia. Crit Care Med 2007; 35(9): 2224-5.
63. Hoye AT, Davoren JE, Wipf P, Fink MP, Kagan VE. Targeting mitochondria. Acc Chem Res 2008; 41(1): 87-97.
64. Balestra GM, Legrand M, Ince C. Microcirculation and mitochondria in sepsis: getting out of breath. Curr Opin Anaesthesiol 2009; 22(2): 184-90.
65. Al-Sadi R, Boivin M, Ma T. Mechanism of cytokine modulation of epithelial tight junction barrier. Front Biosci 2009; 14: 2765-78.
66. Fink MP, Delude RL. Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular level. Crit Care Clin 2005; 21(2): 177-96.
67. Yang R, Miki K, Oksala N, Nakao A, Lindgren L, Killeen ME, et al. Bile high-mobility group box 1 contributes to gut barrier dysfunction in experimental endotoxemia. Am J Physiol Regul Integr Comp Physiol 2009; 297(2): R362-9.
68. Fink MP. Sepsis, ghrelin, the cholinergic anti-inflammatory pathway, gut mucosal hyperpermeability and high mobility group box 1. Crit Care Med 2009; 37(8): 2421-6.
69. Fink MP. Intestinal epithelial hyperpermeability: update on the pathogenesis of gut mucosal barrier dysfunction in critical illness. Curr Opin Crit Care 2003; 9(2): 143-51.
70. Costantini TW, Peterson CY, Kroll L, Loomis WH, Putnam JG, Wolf P, et al. Burns, inflammation, and intestinal injury: protective effects of an anti-inflammatory resuscitation strategy. J Trauma 2009; 67(6): 1162-8.
71. Costantini TW, Loomis WH, Putnam JG, Drusinsky D, Deree J, Choi S, et al. Burn-induced gut barrier injury is attenuated by phosphodiesterase inhibition: effects on tight junction structural proteins. Shock 2009; 31(4): 416-22.
72. Zhang JB, Du XG, Zhang H, Li ML, Xiao G, Wu J, et al. Breakdown of the gut barrier in patients with multiple organ dysfunction syndrome is attenuated by continuous blood purification: effects on tight junction structural proteins. Int J Artif Organs 2010; 33(1): 5-14.
73. McConnell KW, Coopersmith CM. Epithelial cells. Crit Care Med 2005; 33(12 Suppl): S520-2.
74. Mongardon N, Dyson A, Singer M. Is MOF an outcome parameter or a transient, adaptive state in critical illness? Curr Opin Crit Care 2009; 15(5): 431-6.